Table 2 Factors affecting neoadjuvant immunotherapy efficacy of NSCLC patients

Gender

 Male

214

116 (54.2)

reference

reference

 Female

16

4 (25.0)

0.282

0.077–0.837

0.033

0.273

0.062–0.981

0.059

Age

 Age ≤ 60

77

39 (50.7)

reference

 Age > 60

153

81 (53.0)

1.096

0.633–1.898

0.743

Pathology

 LUSC

135

71 (52.6)

reference

reference

 LUAD

59

22 (37.3)

0.536

0.283–0.996

0.051

0.690

0.340–1.384

0.298

 Others

36

27 (75.0)

2.704

1.222–6.487

0.018

3.478

1.484–8.842

0.006

Clinical stage

 III

165

85 (51.5)

reference

 I/II

65

35 (53.8)

1.098

0.618–1.959

0.750

Treatment cycles

 Cycles < 4

156

87 (55.8)

reference

 Cycles ≥ 4

74

33 (44.6)

0.664

0.378–1.158

0.150

Smoking history

 Yes

179

95 (53.1)

reference

 No

15

4 (26.7)

0.322

0.087–0.980

0.060

 Unknown

36

21 (58.3)

1.238

0.603–2.594

0.564

COPD

 No

170

79 (46.5)

reference

reference

 Yes

60

41 (68.3)

2.486

1.350–4.708

0.004

2.490

1.295–4.912

0.007

PD-L1 expression

 PD-L1 < 50%

123

57 (46.3)

reference

reference

 PD-L1 ≥ 50%

29

23 (79.3)

4.439

1.785–12.703

0.002

5.235

1.976–16.045

0.002

 Unknown

78

40 (51.3)

1.219

0.691–2.156

0.495

1.229

0.661–2.293

0.515